Hawley Urges DOJ to Open Investigation into Chemical Abortion Drug Manufacturer

Hawley Urges DOJ to Open Investigation into Chemical Abortion Drug Manufacturer

Tuesday, April 14, 2026

WASHINGTON - Today, U.S. Senator Josh Hawley (R-Mo.) sent a letter to Acting Attorney General Todd Blanche, urging the Department of Justice to open an investigation into Danco Laboratories, the manufacturer of the dangerous chemical abortion drug that has harmed thousands of women and ended the lives of countless unborn children. Senator Hawley demanded that the Department fulfill its mandate by investigating Danco's original FDA approval, ongoing regulatory compliance, manufacture and distribution pipeline, potentially deceptive marketing practices, and disclosure of safety risks pertaining to the company's sole product-the chemical abortion drug, mifepristone.

The letter comes after Senator Hawley opened his own investigation into Danco following a press conference he hosted that featured powerful testimonies from women harmed by mifepristone. Senator Hawley also introduced legislation to ban mifepristone's FDA approval for abortion and empower victims to sue manufacturers of the chemical abortion drugs.

Senator Hawley wrote, "I write to urge you to open an investigation into Danco Laboratories and its manufacture, distribution, and marketing practices relating to mifepristone. Women are being harmed by this chemical abortion drug at far higher rates than advertised on the drug label. As you may know, this drug is now responsible for over 70 percent of abortions in the United States-a number which has risen in just the last four years."

"Very little information is publicly available about Danco Laboratories. The company first introduced mifepristone in the United States in 2000 and, in doing so, appears to have taken unusual and extreme measures to protect itself from liability…Yet Danco is profiting at the expense of women who have taken the drug and been seriously harmed by it. The largest study of mifepristone ever conducted found that nearly 11% of women who take the drug experience a "serious adverse health event," such as sepsis or hemorrhaging. That rate amounts to 22 times higher than what Danco admits to on its label," he continued.

Senator Hawley concluded, "The American public demands answers to the chemical abortion drug that is flooding into every corner of the country-often contrary to state laws-and causing devastating harm to women and babies. I await your response confirming the initiation of your investigation."

Read the full letter here or below.

Todd Blanche

United States Department of Justice

Acting United States Attorney General

950 Pennsylvania Avenue, N.W.

Washington, D.C. 20530

Dear Acting Attorney General Blanche:

I write to urge you to open an investigation into Danco Laboratories and its manufacture, distribution, and marketing practices relating to mifepristone. Women are being harmed by this chemical abortion drug at far higher rates than advertised on the drug label. As you may know, this drug is now responsible for over 70 percent of abortions in the United States-a number which has risen in just the last four years. Large, secretive pharmaceutical corporations like Danco must be held accountable for these serious safety risks to women and the Department should take immediate action.

Very little information is publicly available about Danco Laboratories. The company first introduced mifepristone in the United States in 2000 and, in doing so, appears to have taken unusual and extreme measures to protect itself from liability. It was incorporated in the Cayman Islands. Its board of directors and investors remain secret. And its corporate structure remains largely shielded from public view. Early backers appear to have included George Soros and other far-left activists who favor population control. We do know, however, that chemical abortion is a lucrative enterprise for Danco-so lucrative, in fact, that mifepristone is the only drug the company makes, with investors' returns reportedly topping 450%.

Yet Danco is profiting at the expense of women who have taken the drug and been seriously harmed by it. The largest study of mifepristone ever conducted found that nearly 11% of women who take the drug experience a "serious adverse health event," such as sepsis or hemorrhaging. That rate amounts to 22 times higher than what Danco admits to on its label. I recently hosted an event which featured firsthand testimonies of women who were harmed by the drug. These women deserve justice for what they suffered at the hands of this shady Big Pharma company.

You and the Department of Justice are tasked with upholding the rule of law and protecting every American-including women that companies like Danco prey on and lie to. This mandate includes ensuring Danco's prompt, fulsome, and transparent compliance with all applicable laws, regulations, and ongoing regulatory obligations. My Subcommittee has opened an investigation into Danco and its business practices. I request that you also open an investigation into Danco, including but not limited to its original FDA approval, ongoing regulatory compliance, and distribution pipeline, potentially deceptive marketing practices, and disclosure of safety risks pertaining to the drug.

The American public demands answers to the chemical abortion drug that is flooding into every corner of the country-often contrary to state laws-and causing devastating harm to women and babies. I await your response confirming the initiation of your investigation.

Sincerely,

Josh Hawley

United States Senator

Chairman

Subcommittee on Crime and Counterterrorism

Issues